NCT06981091View on ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

January 8, 2027

Study Completion Date

April 28, 2027

Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
OTHER

XH-S004 20 mg

Administered once per day for 24 weeks.

OTHER

XH-S004 40 mg

Administered once per day for 24 weeks.

OTHER

Placebo

Administered once per day for 24 weeks.

Trial Locations (1)

200040

Huadong Hospital Affiliated to fudan univercity, Shanghai

All Listed Sponsors
lead

S-INFINITY Pharmaceuticals Co., Ltd

INDUSTRY